Announced
Completed
Financials
Tags
France
Cross Border
Private
Friendly
biotechnology
Biotechnology
Acquisition
Completed
Single Bidder
Majority
Synopsis
NorthX Biologics, a Nordic development and manufacturing organisation, completed the acquisition of a biologics manufacturing unit from Valneva, a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines. Financial terms were not disclosed. “I am very proud when looking back at what we have achieved within the unit over the past years and look forward with great enthusiasm to build on NorthX’s position as the go-to manufacturer of advanced biologics in Northern Europe," Janet Hoogstraate, Valneva Sweden Managing Director.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.